These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7107368)

  • 41. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C; Mori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytocidal effects of misonidazole, Ro 03-8799, and RSU-1164 on euoxic and hypoxic BP-8 murine sarcoma cells at normal and elevated temperatures.
    Hofer KG; Lakkis M; Hofer MG
    Cancer; 1989 Apr; 63(8):1501-8. PubMed ID: 2924258
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-cyclopenteno[b]quinoline hydrochloride (NLCPQ-1). A novel DNA-affinic bioreductive agent as cytotoxin and radiosensitizer.
    Papadopoulou MV; Ji M; Rao MK; Bloomer WD
    Oncol Res; 1996; 8(10-11):425-34. PubMed ID: 9114435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma concentrations and pharmacokinetics of misonidazole after intraperitoneal administration to the mouse.
    Malmary-Nebot MF; Labat C; Terrissol M; Martin B; Oustrin J
    Eur J Drug Metab Pharmacokinet; 1982; 7(1):17-20. PubMed ID: 7067719
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of whole body hyperthermia on the pharmacokinetics and toxicity of the basic 2-nitroimidazole radiosensitizer Ro 03-8799 in mice.
    Walton MI; Bleehen NM; Workman P
    Br J Cancer; 1987 May; 55(5):469-76. PubMed ID: 3606940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polarographic measurement of misonidazole in mouse mammary tumors.
    Ohizumi Y; Maezawa H; Murayama C; Mori T
    Tokai J Exp Clin Med; 1984 Aug; 9(3):199-206. PubMed ID: 6537667
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolism induced binding of 14C-misonidazole to hypoxic cells: kinetic dependence on oxygen concentration and misonidazole concentration.
    Koch CJ; Stobbe CC; Baer KA
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1327-31. PubMed ID: 6469755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
    Newman HF; Bleehen NM; Workman P
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
    White RA; Workman P
    Br J Cancer; 1980 Feb; 41(2):268-76. PubMed ID: 7370166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancement of artificial lung metastases by misonidazole.
    Rockwell S; Nierenburg M; Irvin CG
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1395-8. PubMed ID: 6469763
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo radiosensitization by 2-nitroimidazoles more electron-affinic than misonidazole.
    Brown DM; Yu NY; Brown JM; Lee WW
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):435-8. PubMed ID: 7107364
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The radiosensitizing effect of metronidazole and misonidazole (Ro-07-0582) on a human malignant melanoma grown in the athymic mutant nude mouse.
    Rofstad EK; Brustad T
    Br J Radiol; 1978 May; 51(605):381-6. PubMed ID: 638410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical phase I study of the hypoxic cell radiosensitizer RO-07-0582, a 2-nitroimidazole derivative.
    Urtasun RC; Band P; Chapman JD; Rabin HR; Wilson AF; Fryer CG
    Radiology; 1977 Mar; 122(3):801-4. PubMed ID: 841074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Further characterization of 4-bromomisonidazole as a potential detector of hypoxic cells.
    Rasey JS; Krohn KA; Grunbaum Z; Conroy PJ; Bauer K; Sutherland RM
    Radiat Res; 1985 Apr; 102(1):76-85. PubMed ID: 3983371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of binding of [3H]misonidazole and [14C]misonidazole in multicell spheroids.
    Rasey JS; Grunbaum Z; Krohn K; Nelson N; Chin L
    Radiat Res; 1985 Mar; 101(3):473-9. PubMed ID: 3983363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lack of stereoselectivity in the pharmacokinetics and metabolism of the radiosensitizer Ro 03-8799 in man.
    Workman P; Newman HF; Bleehen NM; Ward R; Smithen CE
    Cancer Chemother Pharmacol; 1991; 28(2):118-22. PubMed ID: 2060082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione.
    DeGraff WG; Russo A; Gamson J; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1021-4. PubMed ID: 2522917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Demonstration of tumor-selective retention of fluorinated nitroimidazole probes by 19F magnetic resonance spectroscopy in vivo.
    Maxwell RJ; Workman P; Griffiths JR
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):925-9. PubMed ID: 2703398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. SR-2508: a 2-nitroimidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use.
    Brown JM; Yu NY; Brown DM; Lee WW
    Int J Radiat Oncol Biol Phys; 1981 Jun; 7(6):695-703. PubMed ID: 6457018
    [No Abstract]   [Full Text] [Related]  

  • 60. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK; Hurst S; Begg AC; Brown JM
    Cancer Clin Trials; 1980; 3(3):257-65. PubMed ID: 7438323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.